Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
  • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/53—Colony-stimulating factor [CSF]
  • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/555—Interferons [IFN]
  • C07K14/56—IFN-alpha
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to proteins or analogs thereof (the term "protein” as used herein is synonymous with “polypeptide” or “peptide” unless otherwise indicated) .
• the present invention also relates to novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions.
• the present invention relates to novel N-terminally chemically modified G-CSF compositions and related methods of preparation.
• the present invention also relates to chemically modified consensus interferon.
• PEG Polyethylene glycol
• pegylate meaning to attach at least one PEG molecule
• Adagen a pegylated formulation of adenosine deaminase is approved for treating severe combined immunodeficiency disease; pegylated superoxide dismutase has been in clinical trials for treating head injury; pegylated alpha interferon has been tested in phase I clinical trials for treating hepatitis; pegylated glucocerebrosidase and pegylated hemoglobin are reported to have been in preclinical testing.
• water soluble polymers such as copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3, 6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers) .
• polyethylene glycol For polyethylene glycol, a variety of means have been used to attach the polyethylene glycol molecules to the protein. Generally, polyethylene glycol molecules are connected to the protein via a reactive group found on the protein. Amino groups, such as those on lysine residues or at the N-terminus, are convenient for such attachment. For example, Royer (U.S. Pat. No. 4,002,531, above) states that reductive alkylation was used for attachment of polyethylene glycol molecules to an enzyme.
• EP 0 539 167, published April 28, 1993, Wright, "Peg Imidates and Protein Derivates Thereof” states that peptides and organic compounds with free amino group(s) are modified with an immediate derivative of PEG or related water-soluble organic polymers.
• G-CSF granulocyte colony stimulating factor
• Modified G-CSF and analogs thereof are also reported in EP 0 473 268, published March 4, 1992, entitled “Continuous Release Pharmaceutical Compositions Comprising a Polypeptide Covalently Conjugated To A Water Soluble Polymer," stating the use of various G-CSF and derivatives covalently conjugated to a water soluble particle polymer, such as polyethylene glycol.
• a modified polypeptide having human granulocyte colony stimulating factor activity is reported in EP 0 335 423 published October 4, 1989.
• Another example is pegylated IL-6, EP 0 442 724, entitled, “Modified hIL-6, " .see co-pending U.S.S.N. 07/632,070) which discloses polyethylene glycol molecules added to IL-6.
• EP 0 154 316 published September 11, 1985 reports reacting a lymphokine with an aldehyde of polyethylene glycol.
• protein molecules with five lysine residues reacted in the above methods may result in a heterogenous mixture, some having six polyethylene glycol moieties, some five, some four, some three, some two, some one and some zero. And, among the molecules with several, the polyethylene glycol moieties may not be attached at the same location on different molecules. This is disadvantageous when developing a therapeutic pegylated protein product. In such development, predictability of biological activity is crucial. For example, it has been shown that in the case of nonselective conjugation of superoxide dismutase with polyethylene glycol, several fractions of the modified enzyme were completely inactive (P.McGoff et al. Chem. Pharm. Bull. -3079-3091 (1988)).
• the present invention relates to substantially homogenous preparations of N-terminally chemically modified proteins, and methods therefor.
• chemical modification at the N-terminus of G-CSF demonstrated advantages in stability which are not seen in other G-CSF species containing one chemical modification at another location on the molecule.
• the end product — protein with an a ine linkage to the water soluble polymer — was found to be far more stable than identical polymer/protein conjugate having an amide linkage.
• One other protein so modified (as described in a working example below) is consensus interferon.
• the present invention has a number of aspects relating to chemically modifying proteins (or analogs thereof) as well as specific modifications of specific proteins.
• the present invention relates to a substantially homogenous preparation of N-terminally chemically modified G-CSF (or analog thereof) and related methods.
• N-terminally monopegylated G-CSF more stable than other types of monopegylated G-CSF.
• N-terminus of the G-CSF molecule is more available during reaction with polyethylene glycol, a higher proportion of the N-termini are pegylated, and therefore, this species provides processing advantages.
• the present invention also relates to a type of reductive alkylation which selectively activates ⁇ -amino group of the N-terminal residue of a protein or analog thereof, thereby providing for selective attachment of a water soluble polymer moiety at the N-terminus.
• This provides for a substantially homogenous preparation of polymer/protein conjugate molecules as well as (if polyethylene glycol is used) a preparation of pegylated protein molecules having the polyethylene glycol moiety directly coupled to the protein moiety. This method is described below for G-CSF and for consensus interferon, and these provide for additional aspects of the present invention.
• FIGURE 1A is a reproduction of the chromatogram of the peaks from ion exchange chromatography of pegylated G-CSF.
• FIGURE IB is an SDS-PAGE of various species of mono-pegylated G-CSF.
• FIGURE 2 is an SEC-HPLC profile of (Line A) recombinant human methionyl G-CSF standard; (Line B) SCM-PEG-GCSF reaction mix; (Line C) N-terminally pegylated G-CSF; (Line D) lysine 35 monopegylated G-CSF; (Line E) lysine 41 monopegylated G-CSF.
• FIGURES 3A, 3B, and 3C are HPLC endoproteinase SV8 peptide mapping tracings of (3A) N-terminally pegylated G-CSF; (3B) lysine 35 monopegylated G-CSF; (3C) lysine 41 monopegylated G-CSF.
• FIGURE 4 is a bar graph illustrating a comparison of in vitro bioactivity of monopegylated G- CSF species compared to an unpegylated standard.
• FIGURES 5A and 5B are graphs illustrating results of in vivo bioactivity assays of monopegylated G-CSF derivatives, with 5A illustrating the average hamster white blood cell count after a single subcutaneous injection of N-terminally pegylated G-CSF, lysine 35 monopegylated G-CSF, or lysine 41 monopegylated G-CSF, and 5B illustrating the net average white blood cell count area under the curve after a single subcutaneous injection of the various monopegylated G-CSF derivatives listed above.
• FIGURES 6A, 6B, and 6C are SEC-HPLC profiles for stability studies of N-terminally pegylated G-CSF or lysine 35 monopegylated G-CSF.
• FIGURES 6A and 6B are the profiles for stability studies conducted at pH 6.0 at 4°C for (6A) N-terminally monopegylated G-CSF or (6B) lysine 35 monopegylated G-CSF.
• FIGURE 6C shows the profiles for extended stability studies at pH 6.0 and 4°C for lysine 35 monopegylated G-CSF. Time (“T”) indicates days.
• FIGURE 7 illustrates size exclusion HPLC analysis of the reaction mixture in the process of reductive alkylation of rh-G-CSF with methoxypolyethylene glycol aldehyde (MW 6 kDa) .
• FIGURE 9 illustrates the total white blood cell response after a single subcutaneous dose to mono-N terminal MPEG-GCSF conjugates prepared by reductive alkylation of rh-G-CSF with MPEG aldehydes of different molecular weights (6 kDa,12kDa and 20 kDa).
• the present invention relates to substantially homogenous preparations of N-terminally chemically modified proteins, and methods therefor.
• the present invention relates to N-terminally chemically modified G-CSF compositions and methods therefor.
• the present methods provide for a substantially homogenous mixture of monopolymer/protein conjugate.
• substantially homogenous as used herein means that the only polymer/protein conjugate molecules observed are those having one polymer moiety.
• the preparation may contain unreacted (i.e., lacking polymer moiety) protein.
• peptide mapping and N-terminal sequencing one example below provides for a preparation which is at least 90% monopolymer/protein conjugate, and at most 10% unreacted protein.
• the N-terminally monopegylated material is at least 95% of the preparation (as in the working example below) and most preferably, the N-terminally monopegylated material is 99% of the preparation or more.
• the monopolymer/protein conjugate has biological activity.
• the present "substantially homogenous" N-terminally pegylated G-CSF preparations provided herein are those which are homogenous enough to display the advantages of a homogenous preparation, e.g., ease in clinical application in predictability of lot to lot pharmacokinetics.
• G-CSF which, as described above, is a therapeutic protein used to treat he atopoietic disorders.
• G-CSF useful in the practice of this invention may be a form isolated from mammalian organisms or, alternatively, a product of chemical synthetic procedures or of prokaryotic or eukaryotic host expression of exogenous DNA sequences obtained by genomic or cDNA cloning or by DNA synthesis.
• Suitable prokaryotic hosts include various bacteria (e.g., E « coli) : suitable eukaryotic hosts include yeast (e.g., £. cerevisiae) and mammalian cells (e.g., Chinese hamster ovary cells, monkey cells) .
• the G-CSF expression product may be glycosylated with mammalian or other eukaryotic carbohydrates, or it may be non-glycosylated.
• the G-CSF expression product may also include an initial methionine amino acid residue (at position -1) .
• the present invention contemplates the use of any and all such forms of G-CSF, although recombinant G-CSF, especially E * . coli derived, is preferred, for, among other things, greatest commercial practicality.
• G-CSF analogs have been reported to be biologically functional, and these may also be chemically modified, by, for example, the addition of one or more polyethylene glycol molecules. G-CSF analogs are reported in U.S. Patent No. 4,810,643. Examples of other G-CSF analogs which have been reported to have biological activity are those set forth in
• the G-CSFs and analogs thereof useful in the present invention may be ascertained by practicing the chemical modification procedures as provided herein to selectively chemically modify the N-terminal ⁇ -amino group, and testing the resultant product for the desired biological characteristic, such as the biological activity assays provided herein.
• the desired biological characteristic such as the biological activity assays provided herein.
• recombinant non-human G-CSF*s such as recombinant murine, bovine, canine, etc. See PCT WO
• G-CSF analogs may include those having amino acid additions, deletions and/or substitutions (as compared to the G-CSF amino acid sequence set forth in Example 1, below) .
• Those G-CSF analogs which are predicted to function when N-terminally pegylated to selectively stimulate the production of neutrophils are those with an N-terminus which is not necessary for binding to a G-CSF receptor. See Hill et al., PNAS-USA _ ⁇ S_: 5167-5171 (1993); ___& also PCT US94/00913.
• the polymer molecules used may be selected from among water soluble polymers.
• the polymers should have a single reactive aldehyde.
• the polymer selected should be water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment.
• the polymer selected should have a single reactive aldehyde so that the degree of polymerization may be controlled as provided for in the present methods.
• the polymer may be branched or unbranched.
• the polymer will be pharmaceutically acceptable.
• the water soluble polymer may be selected from the group consisting of, for example, those listed above (in the Background section), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide - 13 -
• co-polymers polyoxyethylated polyols and polyvinyl alcohol.
• the polymer may be of any molecular weight, and may be branched or unbranched.
• the preferred molecular weight is between about 2kDa and about lOOkDa (the term "about” indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) .
• Examples 1 and 2 below involve the use of PEG 6000, which was selected for ease in purification and for providing an adequate model system.
• One specific aspect of the present invention is N-terminally monopegylated G-CSF comprised of a polyethylene glycol moiety and a G-CSF moiety.
• compositions For the present compositions, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to G-CSF protein molecules in the reaction mix, the type of pegylation reaction to be performed, the method of obtaining the selected N-terminally pegylated G-CSF, and the type of G-CSF to be used. Further, the present compositions and methods include formulation of pharmaceutical compositions, methods of treatment and manufacture of medicaments.
• the proportion of polyethylene glycol molecules to protein molecules will vary, as will their concentrations in the reaction mixture. In general, the optimum ratio (in terms of efficiency of reaction in that there is no excess unreacted protein or polymer) will be determined by the molecular weight of the polyethylene glycol selected. In addition, as one example of the present methods involves non-specific pegylation and later purification of N-terminally monopegylated species, the ratio may depend on the number of available reactive groups (typically «or 3 amino groups) available. One working example herein involved a fairly low reaction ratio of protein:PEG molecules to obtain monopegylated material generally (1.5 PEG molecules per protein molecules).
• the method for pegylation may also be selected from among various methods, as discussed above, or the present reductive alkylation as described in Example 2, below.
• a method involving no linking group between the polyethylene glycol moiety and the protein moiety is described in Francis et al., In: Stability of protein pharmaceuticals: in vivo pathways of degradation and strategies for protein stabilization (Eds. Ahern., T.
• the method of obtaining the N-terminally pegylated G-CSF preparation may be by purification of the N-terminally pegylated material from a population of pegylated G-CSF molecules.
• pegylated G-CSF is first separated by ion exchange chromatography to obtain material having a charge characteristic of monopegylated material (other multi-pegylated material having the same apparent charge may be present) , and then the monopegylated materials are separated using size exclusion chromatography.
• N-terminally monopegylated G-CSF was separated from other monopegylated species, as well as other multi-pegylated species.
• Other methods are reported.
• the present invention provides a method for selectively obtaining an N-terminally chemically modified protein (or analog) .
• a method of protein modification by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein.
• substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.
• the reaction is performed at pH which allows one to take advantage of the pK a differences between the ⁇ -amino groups of the lysine residues and that of the ⁇ -amino group of the N-terminal residue of the protein.
• the present invention provides for a method of making a substantially homogenous preparation of monopolymer/protein conjugate molecules, in the absence of further extensive purification as is required using other chemical modification chemistries. Additionally, the product having an amine linkage is unexpectedly more stable than a product produced with an amide linkage, and this is demonstrated in the aggregation studies below. More specifically, if polyethylene glycol is used, the present invention also provides for N-terminally pegylated protein lacking possibly antigenic linkage groups, and having the polyethylene glycol moiety directly coupled to the protein moiety without toxic by-products.
• reaction may be diagrammed as follows (indicating sodium cyanohydroboride as an illustrative reducing agent) :
• one aspect of the present invention is a method for preparing a polymer/protein conjugate comprised of (a) reacting a protein moiety having more than one amino group with a water soluble polymer moiety under reducing alkylation conditions, at a pH suitable to selectively activate the ⁇ -amino group at the amino terminus of said protein moiety so that said water soluble polymer selectively attaches to said ⁇ -amino group; and (b) obtaining the reaction product.
• One may optionally, and preferably for a therapeutic product, separate the reaction products from unreacted moieties.
• monopolymer/ protein conjugate is used here to mean a composition comprised of a single polymer moiety attached to a protein moiety (also encompassed are those conjugates using protein analogs as described herein) .
• the monopolymer/protein conjugate will have a polymer moiety located at the N-terminus, but not on amino side groups, such as those for lysine.
• the preparation will preferably be greater than 80% monopolymer/ protein conjugate, and more preferably greater than 95% monopolymer protein conjugate.
• reaction conditions are those which permit the selective attachment of the water soluble polymer moiety to the N-terminus of the desired protein.
• Such reaction conditions generally provide for pK a differences between the lysine amino groups and the ⁇ -amino group at the N-terminus (the pK being the pH at which 50% of the amino groups are protonated and 50% are not) .
• pK being the pH at which 50% of the amino groups are protonated and 50% are not
• different pH's may be used for optimally modifying the ⁇ -amino groups of the
• the pH also affects the ratio of polymer to protein to be used. In general, if the pH is lower than the pK, a larger excess of polymer to protein will be desired (i.e., the less reactive the N-terminal ⁇ -amino group, the more polymer needed to achieve optimal conditions) . If the pH is higher than the pK, the polymer:protein ratio need not be as large (i.e., more reactive groups are available, so fewer polymer molecules are needed) .
• the molecular weight of the polymer is the higher the molecular weight of the polymer, the fewer number of polymer molecules which may be attached to the protein. Similarly, branching of the polymer should be taken into account when optimizing these parameters. Generally, the higher the molecular weight (or the more branches) the higher the polymer:protein ratio.
• the reducing agent should be stable in aqueous solution and preferably be able to reduce only the Schiff base formed in the initial process of reductive alkylation.
• Preferred reducing agents may be selected from the group consisting of sodium borohydride, sodium cyanoborohydride, dimethylamine borate, timethylamine borate and pyridine borate.
• Sodium cyanoborohydride was used in the working examples below.
• the water soluble polymer may be of the type described above, and should have a single reactive aldehyde for coupling to the protein.
• polyethylene glycol use of PEG 6000 for coupling to G-CSF and PEG 12000 for consensus interferon are described below. It is noted, that for G-CSF, PEG 12000, 20000 and 25000 have also been used successfully in the present methods.
• Polyethylene glycol propionaldenhyde see, e.g., U.S. Patent No. 5,252,714) is advantageous for its stability in water.
• the present methods are broadly applicable to any protein or analog thereof having an N-terminal ⁇ -amino group.
• proteins which are the product of an exogenous DNA sequence expressed in bacteria may have, as a result of bacterially expression, an N-terminal methionyl residue with an ⁇ -amino group.
• peptides are included, as are peptidomimetics and other modified proteins. Protein analogs, such as the G-CSF analogs described above, and the non-naturally occurring consensus interferon are also suitable for the present methods.
• any of the G-CSF's or analogs as described herein may be used (e.g., those described supra) .
• the working examples below use recombinant G-CSF produced in bacteria, having 174 amino acids and an extra N-terminal methionyl residue.
• the chemical modification may be performed with any of the water soluble polymers described herein, and the present working examples describe the use of polyethylene glycol.
• Consensus interferon is another protein used in the present working examples. Demonstrated below is the preparation of chemically modified consensus interferon using the present reductive alkylation methods for N-terminal monopegylation. Thus, other aspects of the present invention relate to these preparations.
• consensus human leukocyte interferon referred to here as “consensus interferon,” or “IFN-con” means a nonnaturally- occurring polypeptide, which predominantly includes those amino acid residues that are common to all naturally-occurring human leukocyte interferon subtype sequences and which include, at one or more of those positions where there is no amino acid common to all subtypes, an amino acid which predominantly occurs at that position and in no event includes any amino acid residue which is not extant in that position in at least one naturally-occurring subtype.
• IFN-con encompasses the amino acid sequences designated IFN-coni, IFN-con2 and IFN-con3 which are disclosed in commonly owned U.S.
• IFN-con DNA sequences encoding IFN-con may be synthesized as described in the above-mentioned patents or other standard methods. IFN-con polypeptides are preferably the products of expression of manufactured DNA sequences, transformed or transfected into bacterial hosts, especially E. coli. That is, IFN-con is recombinant IFN-con. IFN-con is preferably produced in ⁇ _ coli may be purified by procedures known to those skilled in the art and generally described in Klein et al.,J. Chromatog. ____.: 205-215 (1988) for
• Purified IFN-coni may comprise a mixture of isoforms, e.g., purified IFN-coni comprises a mixture of methionyl IFN-coni, des-methionyl IFN-coni and des-methionyl IFN-coni with a blocked N-terminus (Klein et al.. Arc. Biochem. Biophys. 21__ ' 531-537 (1990)).
• IFN-con may comprise a specific, isolated isoform. Isoforms of IFN-con are separated from each other by techniques such as isoelectric focusing which are known to those skilled in the art.
• another aspect of the present invention is a chemically modified consensus interferon wherein said consensus interferon moiety is selected from the group consisting of IFN-coni. IFN-con2, and IFN-con ⁇ .
• the chemical modification is using a water soluble polymer as described herein, such as PEG, and the present reductive alkylation methods may be used for selective N-terminal chemical modification.
• Example 3 herein illustrates a chemically modified IFN coni comprised of an IFN coni moiety connected at the
• the present methods yield pegylated proteins where the polyethylene glycol moiety is directly attached to a protein moiety, and a separate linking group is absent and no toxic by-products are present.
• the examples include G-CSF and consensus interferon as described herein. For a population of pegylated G-CSF protein molecules wherein the polyethylene glycol moiety is directly attached to the G-CSF protein moiety (not necessarily a population of
• N-terminally pegylated G-CSF molecules N-terminally pegylated G-CSF molecules, one may perform the above reductive alkylation with or without an acidic pH.
• compositions of the above may be for administration for injection, or for oral, pulmonary, nasal or other forms of administration.
• pharmaceutical compositions comprising effective amounts of monopolymer/protein conjugate products of the invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers.
• Such compositions include diluents of various buffer content (e.g., Tris-HCl, acetate.
• compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present N-terminally chemically modified proteins. See, e.g.. Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712 which are herein incorporated by reference.
• Conditions alleviated or modulated by the administration of the present polymer/G-CSF conjugates are typically those characterized by a reduced hematopoietic or immune function, and, more specifically, a reduced neutrophil count.
• Such conditions may be induced as a course of therapy for other purposes, such as chemotherapy or radiation therapy.
• infectious disease such as bacterial, viral, fungal or other infectious disease.
• sepsis results from bacterial infection.
• such condition may be hereditary or environmentally caused, such as severe chronic neutropenia or leukemias.
• Age may also play a factor, as in the geriatric setting, patients may have a reduced neutrophil count or reduced neutrophil mobilization.
• Filgrastim r-met Hu G-CSF
• Other less-studied conditions which may be alleviated or modulated by administration of the present polymer/G-CSF conjugates may include the reduction of lipids (or cholesterol) in the blood stream, and certain cardiovascular conditions, as G-CSF may induce production of plasminogen activators.
• G-CSF G-CSF
• a water soluble polymer such as polyethylene glycol
• conditions which may be alleviated or modulated by administration of the present polymer/consensus interferon are those to which consensus interferon is applicable and include cell proliferation disorders, viral infections, and autoimmune disorders such as multiple sclerosis.
• Cf.. McManus Balmer, DICP, The Annals of Pharmacotherapy 2 : 761-767 (1990) (Clinical use of biologic response modifiers in cancer treatment: an overview. Part I. The Interferons) .
• Methods and compositions for the treatment of cell proliferation disorders using consensus interferon are described in PCT WO 92/06707, published April 30, 1992, which is herein incorporated by reference.
• hepatitis may be treatable using the present pegylated consensus interferon molecules.
• the working example below demonstrates that, in vitro, chemically modified consensus interferon has 20% of the biological activity of non-chemically modified consensus interferon.
• dosage levels for treatment of various conditions in various patients will be between 0.01 ⁇ g/kg body weight, (calculating the mass of the protein alone, without chemical modification) , and 100 ⁇ g/kg (based on the same) .
• Example 1 illustrates the advantages of N-terminally pegylated G-CSF as compared to G-CSF monopegylated at lysine-35 or lysine 41 (of the G-CSF met + 174 amino acid version) .
• Example 2 illustrates the present reductive alkylation in N-terminally pegylating G-CSF. The method provides for a substantially homogenous preparation of N-terminally pegylated G-CSF.
• Example 3 illustrates the present reductive alkylation in N-terminally pegylating consensus interferon.
• rhG-CSF Recombinant human met-G-CSF
• r-met-hu-G-CSF Recombinant human met-G-CSF
• the rhG-CSF employed was an E * . coli derived recombinant expression product having the amino acid sequence (encoded by the DNA sequence) shown below (Seq.ID NOs. 1 and 2):
• GGT GTA CTG GTT GCT TCT CAT CTG CAA TCT TTC CTG GAA GTA TCT G V L V A S H L Q S F L E V S
• reaction mixture consisted mainly of three forms of mono-pegylated rh-G- CSF, some di-pegylated rh-G-CSF, unmodified rh-G-CSF and reaction bi-product (N-hydroxy succinimide) .
• results demonstrate that, of the N-terminally monopegylated G-CSF, the samples showed a greater than 95% N-terminally pegylated composition, with the remainder probably being unpegylated material (although the remainder of the samples is lower than the detection limit of the assay) .
• percent monopegylated for each of the three types of monopegylated material N-terminal, pegylated at lysine 35, and pegylated at lysine 41
• the N-terminal and the lysine 41 demonstrated greater than 97% monopegylated.
• the lysine 35 pegylated material being somewhat lower, probably due to the instability of the molecule in the assay conditions.
• N-terminal sequencing as discussed infra is not here considered quantitative, as there may have been artifactual separation of the polyethylene glycol molecule from the N-terminus of the protein during the sequencing process.
• RI/UV refers to the Index of Refraction/Ultraviolet light absorbance ratio, and is used to estimate the number of polyethylene glycol molecules per molecule of protein. It is calculated from the SEC HPLC data using an Index of Refraction for polyethylene glycol and an ultraviolet absorbance for protein.
• Lane 5 contains 10 ⁇ g of monopegylated G-CSF with the pegylation site at the lysine found at the 35th residue from the N-terminal methionine.
• Lane 6 contains 10 ⁇ g of monopegylated G-CSF with the pegylation site at the lysine found at the 41st residue from the N-terminal methionine.
• Lane 3 containing the N-terminally monopegylated material, shows a single band
• this initial peptide should have resulted in a zero initial yield, and the ⁇ 5% yield observed may be from detachment of the polyethylene glycol from the N- terminal methionyl during sequence analysis.
• the sequence detected was that of the N-terminal peptide, M-T-P-L-G-P-A-S-S.
• For "Mono-PEG-2”, (the lysine 35 pegylated material) 80% of the total peak volume was collected for the peak at 66.3 minutes, and was sequenced for 9 cycles. The recovery of lysine 35 was significantly low, indicating pegylation at position 35. The recovery of lysine 41 was consistent with the other residue, indicating no modification of this position.
• the peptide at 30.3 minutes decreased in peak height compared to the corresponding peak in the standard reference map.
• the peptide at 30.3 minutes is only 57.5% of the peak area of the corresponding peptide.
• the sequence detected for this species was K-L-C-A-T-Y-K-L.
• the lysine 41 material 80% of the total peak volume collected for the peptide eluting> at 66.4 minutes was sequenced for 9 cycles.
• the sequence detected was K-L-C-A-T * Y-K-L, and contained lysine residues 35 and 41.
• the recovery of lysine 35 was consistent with other residue recoveries.
• the recovery of lysine 41 was significantly lower indicating pegylation at position 41.
• FIGURE 4 illustrates the results of in vitro assays. As can be seen, the N-terminally monopegylated material had 68% of the activity of non-modified rhG-CSF.
• the G-CSF in vitro bioassay is a mitogenic assay utilizing a G-CSF dependent clone of murine 32D cells. Cells were maintained in Iscoves medium containing 5% FBS and 20 ng/ml rhG-CSF. Prior to sample addition, cells were prepared by rinsing twice with growth medium lacking rhG-CSF.
• In vivo activity confirmed the activity of the N-terminally pegylated material.
• the in vivo testing was carried out by dosing male golden hamsters with a 0.1 mg/kg of sample, using a single subcutaneous injection. Four animals were subjected to terminal bleeds per group per time point. Serum samples were subject to a complete blood count on the same day that the samples were collected. The average white blood cell counts were calculated. As can be seen in FIGURES 5A and 5B, the response from each material peaks after one day following a single subcutaneous injection of 0.1 mg/kg.
• N-terminally pegylated G-CSF and lysine-35 monopegylated G-CSF were studied in two pH levels, pH 4.0 and pH 6.0 at 4°C, each for up to 16 days. Elevating the pH to 6.0 provides an environment for accelerated stability assays.
• pH 6.0 samples N-terminal monopegylated G-CSF and Lysine 35 monopegylated G-CSF as prepared above were placed in a buffer containing 20 mM sodium phosphate, 5 mM sodium acetate, 2.5 % mannitol, 0.005 % Tween-80, pH 6.0 at a final protein concentration of 0.25 mg/ml.
• FIGURES 6A-6C Results are illustrated in FIGURES 6A-6C.
• FIGURE 6A shows the 4°C SEC-HPLC profiles for N-terminally monopegylated G-CSF at pH 6 over time
• FIGURE 6B shows the 4°C SEC-HPLC profiles for lysine-35 monopegylated G-CSF at pH 6 over time.
• Lys-35 material is breaking down to a material with a molecular weight similar to that of unmodified G-CSF.
• FIGURES 6C illustrates the SEC-HPLC profiles for the monopegylated G-CSF's under these conditions, under extended time periods.
• the lysine-35 material exhibits no increase in depegylation at day 16 or day 35 beyond what was seen for day 6 (FIGURE 6B) . This indicates that depegylation (instability) does not change, under those conditions, beyond day 6.
• This example demonstrates a method of preparing a substantially homogenous population of monopegylated G-CSF using reductive alkylation, and characterization of this population.
• Recombinant G-CSF as described in the above example was used.
• the present methods provide advantages in terms of yield of N-terminally chemically modified material, but also, the amine linkages of the present reductive alkylation process produce substantially more stable products as demonstrated by a large difference in the degree of aggregation upon storage.
• A. Preparation of the mono-methoxypolyethylene g.ycol-G SF conjugates with the site of attachment at the N-terminal ⁇ -amino residue.
• FIGURE 1 is a recording of the protein concentration (as determined by absorbance at A280) and shows the peak eluting at 8.72 minutes as monopegylated G-CSF, and a minor peak of unreacted G-CSF eluting at 9.78 minutes.
• FIGURE 8 shows the peaks obtained when using N-hydroxysuccinimidyl ester of MPEG.
• the molecular weight was also 6kDa.
• the mixture obtained from this reaction was: tri-MPEG-GCSF conjugated (shoulder at approximately 7.25 minutes), di-MPEG-GCSF conjugate (peak at 7.62 minutes), mono-MPEG-GCSF conjugate (peak at 8.43 minutes) and unreacted G-CSF (peak at 9.87 minutes) .
• the pH of the reaction mixture was adjusted to pH 4 with 100 mM HCl and the reaction mixture was diluted 5 times with 1 mM HCl.
• the mono-MPEG-GCSF derivative was purified by ion exchange chromatography using HiLoad 16/10 S Sepharose HP column (Pharmacia) equilibrated with 20 mM sodium acetate buffer, pH 4.
• the reaction mixture was loaded on the column at a flow rate of 1 ml/min and the unreacted MPEG aldehyde eluted with three column volumes of the same buffer. Then a linear 400 minute gradient from 0% to 45% 20 mM sodium acetate, pH 4, containing 1 M NaCl was used to the elute the protein-polymer conjugate at 4°C.
• the molecular weight at the monopegylated conjugates was determined by SDS-PAGE, gel filtration, matrix assisted laser desorption mass spectrometry, and equilibrium centrifugation. These results are presented in Table 4, below.
• N-terminal mono-MPEG-GCSF conjugates The structure of the prepared N-terminal mono-MPEG-GCSF conjugates was confirmed using the methods of N-terminal protein sequencing and peptide mapping. Cyanogen bromide cleavage of the N-terminal methionyl residue resulted in removal of the polyethylene glycol.
• the in vitro biological activity of the pegylated MPEG-GCSF conjugates was determined by measuring the stimulated uptake of ⁇ H thymidine into mouse bone marrow cells.
• the in vivo biological activity was determined by subcutaneous injection to hamsters MPEG-GCSF conjugates or rhG-CSF (at lOOmg/kg) and measuring total white blood cell count. Bioactivity as compared to non-derivatized G-CSF was calculated as the area under the WBC/time curve after subtracting the vehicle control curve. Relative bioactivity of the MPEG-GCSF derivatives was expressed as the percentage bioactivity compared to unmodified G-CSF.
• FIGURE 9 is a graph illustrating the total white blood cell response to mono-N-terminal MPEG-GCSF conjugates prepared by reductive alkylation of rhG-CF with MPEG aldehydes of different molecular weights (6kDa, 12kDa, and 20kDa) .
• MPEG aldehydes of different molecular weights (6kDa, 12kDa, and 20kDa) .
• all monopegylated molecules elicited a response.
• N-terminally pegylated G-CSF's prepared by the two different chemistries were compared for the degree of aggregation.
• amide vs. amine of the reductive alkylation here were compared for the degree of aggregation.
• N-terminally pegylated G-CSF using the amine chemistry was found to be substantially more stable than N-terminally pegylated G-CSF with an amide linkage (NHS chemistry as described in Example 1) .
• This example demonstrates chemically modified consensus interferon. More specifically, this example demonstrates a method of preparing a substantially homogenous population of monopegylated IFN-coni, and characterization of this population.
• any of the consensus interferons as set forth above may be chemically modified.
• Such chemical modification may be with any of the water soluble polymers as listed above, although PEG is used here.
• PEG 12000 is used here, although any water soluble PEG species may be used (PEG 12000 was selected for ease in handling and convenience) .
• a variety of means for chemical modification are available (such as acetylation) but, for selective N- terminal chemical modification, such as N-terminal pegylation, the present reductive alkylation method as described in this example is preferred.
• IFN- ⁇ coni (here referred to as IFN-coni) as described in Figure 2 of U.S. Patent No. 4,695,623, which is incorporated by reference in its entirety, was used for the preparation of monopegylated consensus interferon.
• the IFN-coni was produced by expression of exogenous DNA in bacteria, and contained a methionyl residue at the N-terminus.
• the extent of the protein modification during the course of the reaction was monitored by reverse phase HPLC using a polymer-based poly(styrene/divinylbenzene) column, such as PLRP-S (PL Separation Sciences Polymer Laboratories) .
• a polymer-based poly(styrene/divinylbenzene) column such as PLRP-S (PL Separation Sciences Polymer Laboratories) .
• the reverse phase HPLC analysis indicated that 80% of the protein with unblocked ⁇ -amino group at the N-terminus has been converted to the MPEG-IFN-coni derivative.
• the reaction mixture was diluted 5 times with water and the mono-MPEG-IFN-Coni derivative was purified by ion exchange chromatography using HiLoad 16/10 S Sepharose HP column (Pharmacia) equilibrated with 20 mM sodium acetate buffer, pH 4.0.
• the reaction mixture was loaded on the column at a flow rate of 1 ml/min and the unreacted MPEG aldehyde eluted with three column volumes of the same buffer.
• a linear 420 minute gradient from 0% to 75% of 20 mM sodium acetate, pH 4.0, containing 1 M NaCl was used to the elute the protein- polymer conjugate at 4°C.
• the structure of the purified N-terminal mono-MPEG-IFN-coni conjugates was confirmed using the methods of N-terminal protein sequencing and peptide mapping.
• this IFN-coni preparation contained some N-terminally blocked material, and this material was not pegylated. The material which was pegylated, however, was monopegylated at the N-terminus. Thus, in this type of situation, one may wish to use other means to separate the blocked from the unblocked material, such as ion exchange or size exclusion chromatography.
• the in vitro biological activity of the mono-MPEG-IFN Coni conjugates was determined by measuring their antiviral bioactivity.
• the in vitro biological activity of the mono-MPEG-IFN-Coni conjugates was determined by measuring their antiviral bioactivity in human (HeLa) cells.
• the mono-MPEG (12 kDa)-IFN- Coni conjugate shows 20% in vitro bioactivity (in U/mg of protein) when compared to the unmodified species.
• the in vitro assays while useful to demonstrate biological activity, may show a rather low level of activity for chemically modified proteins because of characteristic sustained release.
• the in vivo biological activity may be higher than the in vitro biological activity.
• Protein aggregate and oligo MPEG-IFN-coni conjugate 24% of the total area (eluting at 238.42 ml) ;
• the conditions were not further optimized.
• ATGACTCCAT TAGGTCCTGC TTCTTCTCTG CCGCAAAGCT TTCTGCTGAA ATGTCTGGAA 60
• AAACTGTGCC ATCCGGAAGA GCTGGTACTG CTGGGTCATT CTCTTGGGAT CCCGTGGGCT 180

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Immunology (AREA)
• Gastroenterology & Hepatology (AREA)
• Biochemistry (AREA)
• Toxicology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Zoology (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Epidemiology (AREA)
• Urology & Nephrology (AREA)
• Virology (AREA)
• Vascular Medicine (AREA)
• Neurology (AREA)
• Heart & Thoracic Surgery (AREA)
• Biomedical Technology (AREA)
• Obesity (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Neurosurgery (AREA)
• Cardiology (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Publications (1)

Family

ID=23250903

Family Applications (1)

Country Status (19)

Cited By (180)

Families Citing this family (384)

Citations (3)

Family Cites Families (93)